Cited In for PMID: 29339917

Year	Number of Results
2017	1
2018	2
2019	7
2020	17
2021	20
2022	16
2023	11
2024	6

1

Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients.

Ehlken C, Helms M, Böhringer D, Agostini HT, Stahl A. Ehlken C, et al. Clin Ophthalmol. 2017 Dec 20;12:13-20. doi: 10.2147/OPTH.S151611. eCollection 2018. Clin Ophthalmol. 2017. PMID: 29339917 Free PMC article.

2

The Treatment of Diabetic Retinal Edema with Intravitreal Steroids: How and When.

Salvetat ML, Pellegrini F, Spadea L, Salati C, Musa M, Gagliano C, Zeppieri M. Salvetat ML, et al. J Clin Med. 2024 Feb 26;13(5):1327. doi: 10.3390/jcm13051327. J Clin Med. 2024. PMID: 38592149 Free PMC article. Review.

3

Sustained Disease Control in DME Patients upon Treatment Cessation with Brolucizumab.

Garweg JG, Steinhauer S. Garweg JG, et al. J Clin Med. 2024 Mar 7;13(6):1534. doi: 10.3390/jcm13061534. J Clin Med. 2024. PMID: 38541760 Free PMC article.

4

Understanding Loss to Follow-Up in AMD Patients Receiving VEGF Inhibitor Therapy: Associated Factors and Underlying Reasons.

Kusenda P, Caprnda M, Gabrielova Z, Kukova N, Pavlovic S, Stefanickova J. Kusenda P, et al. Diagnostics (Basel). 2024 Feb 12;14(4):400. doi: 10.3390/diagnostics14040400. Diagnostics (Basel). 2024. PMID: 38396439 Free PMC article.

5

Real-World Experience With Brolucizumab 6 mg for Diabetic Macular Edema.

Bragança F, Ferreira A, Leite J, Coelho J, Borges T, Caiado F, Correia N, Beirão J, Menéres P, Pessoa B. Bragança F, et al. Cureus. 2024 Jan 12;16(1):e52176. doi: 10.7759/cureus.52176. eCollection 2024 Jan. Cureus. 2024. PMID: 38344619 Free PMC article.

6

Patient adherence to therapy after switch to aflibercept from bevacizumab or ranibizumab for treatment-refractory neovascular age-related macular degeneration.

Archambault SD, Nichols MM, McCullum JC, Zhang Y, Steinberger EE, Ramsey DJ. Archambault SD, et al. Indian J Ophthalmol. 2024 Jan 1;72(Suppl 1):S101-S105. doi: 10.4103/IJO.IJO_1795_23. Epub 2023 Dec 22. Indian J Ophthalmol. 2024. PMID: 38131550 Free PMC article.

7

Real-World Outcomes of Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in Türkiye: MARMASIA Study Group Report No. 1.

Yayla U, Sevik MO, Karabaş VL, Şahin Ö, Özkaya A, Yenerel NM, Açıkalın Öncel B, Kaplan FB, Önder Tokuç E, Kanar HS, Kutlutürk Karagöz I, Başaran Emengen E, Demirciler Sönmez A, Aykut A, Limon U, Bozkurt E, Özsoy Saygın I, Aydoğan Gezginaslan T, Aydın Öncü Ö, Türkseven Kumral E, Erçalık NY, Çelik E. Yayla U, et al. Turk J Ophthalmol. 2023 Dec 21;53(6):356-368. doi: 10.4274/tjo.galenos.2023.56249. Turk J Ophthalmol. 2023. PMID: 38126607 Free PMC article.

8

Real-World Persistence and Treatment Interval in Patients with Diabetic Macular Edema Treated with Anti-Vascular Endothelial Growth Factors in the USA.

Bakri SJ, Delyfer MN, Grauslund J, Andersen S, Karcher H. Bakri SJ, et al. Ophthalmol Ther. 2023 Oct;12(5):2465-2477. doi: 10.1007/s40123-023-00750-9. Epub 2023 Jun 22. Ophthalmol Ther. 2023. PMID: 37347405 Free PMC article.

9

Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: a systematic review and meta-analysis.

Shahzad H, Mahmood S, McGee S, Hubbard J, Haque S, Paudyal V, Denniston AK, Hill LJ, Jalal Z. Shahzad H, et al. Syst Rev. 2023 Jun 2;12(1):92. doi: 10.1186/s13643-023-02261-x. Syst Rev. 2023. PMID: 37269003 Free PMC article.

10

Chakraborty D, Mondal S, Boral S, Das A, Sinha TK, Majumdar S, Bhattacharya R, Maitra R. Chakraborty D, et al. Clin Ophthalmol. 2023 Apr 8;17:1067-1076. doi: 10.2147/OPTH.S407219. eCollection 2023. Clin Ophthalmol. 2023. PMID: 37064960 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

64 results

Results by year